drugset / Trial / NCT06938880

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

NCT06938880

Phase 1/2 Recruiting 60 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.

Timeline

Start
2025-05-20
Primary completion
2027-05
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG005 Unknown 10 mg/kg Intravenous
Subject ZG005 Unknown 20 mg/kg Intravenous
Subject ZGGS18 Unknown 10 mg/kg Intravenous

Indications